Gem Aromatics Ltd
Incorporated in October 1997, Gem Aromatics Limited manufactures speciality ingredients, including essential oils, aroma chemicals, and Value-Added Derivatives in India.[1]
- Market Cap ₹ 1,021 Cr.
- Current Price ₹ 195
- High / Low ₹ 350 / 133
- Stock P/E 34.6
- Book Value ₹ 87.1
- Dividend Yield 0.00 %
- ROCE 19.4 %
- ROE 20.7 %
- Face Value ₹ 2.00
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Debtor days have increased from 69.0 to 102 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 314 | 425 | 452 | 504 | 458 | |
| 265 | 359 | 374 | 416 | 389 | |
| Operating Profit | 49 | 66 | 78 | 88 | 70 |
| OPM % | 16% | 16% | 17% | 18% | 15% |
| 3 | 0 | 2 | 2 | 3 | |
| Interest | 3 | 6 | 6 | 8 | 13 |
| Depreciation | 4 | 5 | 6 | 7 | 16 |
| Profit before tax | 44 | 56 | 68 | 75 | 44 |
| Tax % | 30% | 20% | 26% | 29% | |
| 31 | 45 | 50 | 53 | 30 | |
| EPS in Rs | 174.74 | 250.27 | 10.69 | 11.39 | 6.47 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 9 | 9 | 10 |
| Reserves | 136 | 178 | 221 | 275 | 445 |
| 78 | 90 | 112 | 225 | 144 | |
| 23 | 26 | 26 | 26 | 59 | |
| Total Liabilities | 240 | 296 | 369 | 535 | 658 |
| 36 | 36 | 50 | 54 | 217 | |
| CWIP | 1 | 11 | 30 | 126 | 25 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 203 | 249 | 289 | 355 | 416 | |
| Total Assets | 240 | 296 | 369 | 535 | 658 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -5 | 15 | 40 | -25 | |
| -15 | -18 | -50 | -92 | |
| 18 | 6 | 15 | 103 | |
| Net Cash Flow | -2 | 4 | 5 | -15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 46 | 68 | 37 | 102 |
| Inventory Days | 206 | 164 | 187 | 161 |
| Days Payable | 27 | 24 | 20 | 23 |
| Cash Conversion Cycle | 225 | 208 | 203 | 241 |
| Working Capital Days | 110 | 102 | 121 | 116 |
| ROCE % | 25% | 24% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Investor/analyst plant visit on 24-Feb-2026 at Unit 3 Dahej, 11:30–15:30; Q3/9MFY26 presentation to be used.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Plant visit investor meeting with New Berry Advisors at Dahej on 17-Feb-2026; uses Q3 & 9MFY26 presentation.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 9 Feb
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 9 Feb
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
9 Feb - Investor 1-on-1 meetings scheduled Feb 13 and Feb 23, 2026; Q3 & 9MFY26 presentation to be used.
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
Business Profile[1][2]
The company specializes in producing high-quality essential oils, aroma chemicals, and value-added derivatives. It has a strong foundation in mint- and clove-based products and growing capabilities in eucalyptus and phenol derivatives, it offers a portfolio of around 70 products across four categories. These ingredients find wide applications in oral care, cosmetics, nutraceuticals, pharmaceuticals, wellness and pain management, as well as personal care segments.